(800) 853-6498
 
Home > News & Events > News

CAPS News

   

Read news and press releases about CAPS, covering subjects ranging from products, related events, company news and more.

11/30/17

CAPS® to Showcase Its Quality Assurance Programs at ASHP

CAPS News

Contact:   Todd Jones
Central Admixture Pharmacy Services, Inc.  720-590-4871          Todd.Jones@CAPSpharmacy.com


CAPS® to Showcase Its Quality Assurance Programs at ASHP

IRVINE, CA — November 30, 2017 — Central Admixture Pharmacy Services, Inc. (CAPS) will showcase its 503B compounded drugs 100 percent release testing quality assurance program at this year’s American Society of Health-System Pharmacists (ASHP) 52nd Midyear Clinical Meeting.

CAPS has been a front-runner in implementing the Food and Drug Administration’s (FDA) 503B quality assurance requirements under the Drug Quality and Security Act (DQSA). From Dec. 3-7 in the Orange County Convention Center West Concourse, Orlando, Florida, CAPS representatives will be at booth #947 to highlight the company’s Test, Hold and Release (THRSM) program. THR is designed to ensure that every compounded drug batch from CAPS’ 503B outsourcing facilities meets the new standards for cGMP release testing for sterility, potency, and endotoxin prior to shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.

“Our existing high quality standards are further strengthened with THR implementation,” said Mike Koch, Senior Vice President, CAPS Professional Services. “When it comes to patient safety, we believe that 100% release testing from our 503B facilities is the only way to assure the level of quality demanded by our customers.”

CAPS was among the first outsourcing facilities in the nation to fully adopt release testing.

At its booth, CAPS representatives also will introduce the company’s latest 90-Day beyond use dating (BUD) offering for pre-filled syringes and other products, which is designed to improve waste reduction. This initiative further complements CAPS’ current extended BUD offerings. 

“CAPS is at the forefront of helping hospitals and surgery centers navigate through the new compounding regulatory environment,” Koch said. “Our goal is to provide our customers with programs such as THR, and extended BUD to help them focus on improving patient care.”

A market leader in customized Parenteral Nutrition delivery and provider of quality sterile compounding services for the past 25 years, CAPS will also feature CAPS ConsultingSM, a service designed to help hospital pharmacists and pharmacies remain compliant in light of new regulations as a result of the DQSA. CAPS Consulting offers comprehensive evaluations of pharmacies, assesses compliance readiness, and provides recommendations and training. As part of this service, CAPS Consulting offers a ReadyCheckSM quality assurance program – an on-site USP <797> and USP <800> compliance analysis performed by auditors, who conduct a comprehensive assessment of compounding, dispensing, clean room processes, testing and monitoring, media fills, and training. 

To further underscore its commitment to servicing its customers, CAPS is expanding its sterile compounding outsourcing services with a new state-of-the-art, 503B outsourcing facility in Phoenix, AZ. The facility, which is expected to open next summer, will complement its two existing 503B facilities located in San Diego, CA and Allentown, PA.

About CAPS®
CAPS is the nation's largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS currently has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including PN and chemotherapy. To learn more, visit www.CAPSpharmacy.com.

About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.

Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.